Form 13-F position report

PHOENIX BIOTECH ACQUISITION

Reported by Periscope Capital Inc

CEROW CUSIP 71902K113 Manager CIK 0001695320

Reported 957,098 shares, unchanged from the prior quarter.

Reported value 61.5%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 957,098 Quarter-end amount reported
Reported value $61,858 Fair value at quarter end
Consecutive quarters held 6 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 65000
2022-06-30 32000
2022-09-30 86000
2022-12-31 40600
2023-03-31 38301
2023-06-30 61858
2023-09-30 68528
2023-12-31 25635
2024-03-31 40340
2024-06-30 8595
2024-09-30 2170
2024-12-31 2274
2025-03-31 3973
2025-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for PHOENIX BIOTECH ACQUISITION held by Periscope Capital Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2025 Reduced 0 -274,000 (-100.0%) 0 $0 2025-08-14
Q1 2025 Unchanged 274,000 0 (0.0%) < 0.01% $3,973 2025-05-13
Q4 2024 Reduced 274,000 -151,534 (-35.6%) < 0.01% $2,274 2025-02-10
Q3 2024 Reduced 425,534 -2,100 (-0.5%) < 0.01% $2,170 2024-11-12
Q2 2024 Reduced 427,634 -163,866 (-27.7%) < 0.01% $8,595 2024-08-13
Q1 2024 Reduced 591,500 -365,598 (-38.2%) 0.01% $40,340 2024-05-13
Q4 2023 Unchanged 957,098 0 (0.0%) < 0.01% $25,635 2024-02-13
Q3 2023 Unchanged 957,098 0 (0.0%) < 0.01% $68,528 2023-11-06
Q2 2023 Unchanged 957,098 0 (0.0%) < 0.01% $61,858 2023-08-14
Q1 2023 Unchanged 957,098 0 (0.0%) < 0.01% $38,301 2023-05-12
Q4 2022 Added 957,098 +26,300 (2.8%) < 0.01% $40,600 2023-02-13
Q3 2022 Added 930,798 +630,998 (210.5%) < 0.01% $86,000 2022-11-08
Q2 2022 Unchanged 299,800 0 (0.0%) < 0.01% $32,000 2022-08-15
Q1 2022 New 299,800 +299,800 (0.0%) < 0.01% $65,000 2022-05-16

Who else reported the position

49 managers reported PHOENIX BIOTECH ACQUISITION for Q2 2023.

Managers reporting PHOENIX BIOTECH ACQUISITION in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MANGROVE PARTNERS Unchanged 163,538 0 0.12% $1,782,564 7 qtrs
Periscope Capital Inc This report Unchanged 957,098 0 < 0.01% $61,858 6 qtrs
Segantii Capital Management Ltd Unchanged 5,000 0 < 0.01% $54,500 7 qtrs
HIGHBRIDGE CAPITAL MANAGEMENT LLC Added 714,827 +136,983 < 0.01% $43,604 7 qtrs
MMCAP International Inc SPC Unchanged 375,000 0 < 0.01% $22,913 7 qtrs
CANTOR FITZGERALD L P Unchanged 363,548 0 < 0.01% $22,213 7 qtrs
Saba Capital Management L P Unchanged 295,913 0 < 0.01% $19,368 7 qtrs
Polar Asset Management Partners Inc Unchanged 300,000 0 < 0.01% $18,330 7 qtrs
Linden Advisors LP Unchanged 249,999 0 < 0.01% $16,375 6 qtrs
AQR Arbitrage LLC Reduced 246,696 -286 < 0.01% $15,073 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
*W EXP 09/01/202

Voting authority reported

Sole
0
Shared
0
None
957,098

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.